about
Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical productionProspects of In vivo Incorporation of Non-canonical Amino Acids for the Chemical Diversification of Antimicrobial PeptidesNano-engineering the Antimicrobial Spectrum of Lantibiotics: Activity of Nisin against Gram Negative Bacteria.Synergistic Nisin-Polymyxin Combinations for the Control of Pseudomonas Biofilm Formation.Identification of Key Residues in the NisK Sensor Region for Nisin Biosynthesis Regulation.Using bacterial genomes and essential genes for the development of new antibiotics.Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies.Towards Biocontained Cell Factories: An Evolutionarily Adapted Escherichia coli Strain Produces a New-to-nature Bioactive Lantibiotic Containing Thienopyrrole-Alanine.Novel Group of Leaderless Multipeptide Bacteriocins from Gram-Positive Bacteria.Whole-genome sequencing of mutants with increased resistance against the two-peptide bacteriocin plantaricin JK reveals a putative receptor and potential docking site.EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics.Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.Fighting biofilms with lantibiotics and other groups of bacteriocins.OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.Processing and Structure of the Lantibiotic Peptide Nso From the Human Gut Bacterium Blautia obeum A2-162 analysed by Mass Spectrometry.
P2860
Q26748638-C88146F5-2823-4D4A-854F-5D1B79B42EEBQ28817674-CB853FDA-4DEB-4627-8B53-4E22F15C7C2FQ33849047-CE54F0B0-CB8F-43A4-A24E-5AE8B3E0E03AQ37366258-D09EB351-9D53-4291-84D2-67DCE4AD1F91Q37607123-4680D6CF-698C-4961-95E5-7DB62A7CD3DDQ39035296-1F90C8FA-9A7E-4466-BF48-1D8DB77B13FBQ39065285-97ED9136-ACE3-4FD4-A3DF-7CA8D483C7C6Q41107514-269EDA92-D9AF-490D-B6A0-11DA77EDEB93Q41717646-86C18A6D-5ADE-448C-9064-F9C61BBCCDB1Q42361574-621BB5E9-7483-4FED-B3CF-AA03095E444EQ47158624-30C3B8B8-A15B-4AA0-A8EF-AD51C60BCD85Q50033661-FF0297EB-1C47-4D13-819E-D833EAA292C3Q52608578-F30E8A2C-7817-4069-855D-954771522374Q55223927-C23C4229-A017-4AC8-AE9B-21AAC7A52126Q55307893-5A08D467-7507-4712-9581-4EBD8DC11515Q55650113-9AE961BE-5A46-4CB8-816B-F1999F781D84
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Bioengineering Lantibiotics for Therapeutic Success
@ast
Bioengineering Lantibiotics for Therapeutic Success
@en
Bioengineering Lantibiotics for Therapeutic Success
@nl
type
label
Bioengineering Lantibiotics for Therapeutic Success
@ast
Bioengineering Lantibiotics for Therapeutic Success
@en
Bioengineering Lantibiotics for Therapeutic Success
@nl
prefLabel
Bioengineering Lantibiotics for Therapeutic Success
@ast
Bioengineering Lantibiotics for Therapeutic Success
@en
Bioengineering Lantibiotics for Therapeutic Success
@nl
P2093
P2860
P50
P3181
P356
P1476
Bioengineering Lantibiotics for Therapeutic Success
@en
P2093
Colin Hill
Paul D Cotter
P2860
P3181
P356
10.3389/FMICB.2015.01363
P407
P577
2015-01-01T00:00:00Z